These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 15842551)

  • 21. Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration.
    Fernández-Varón E; Bovaira MJ; Espuny A; Escudero E; Vancraeynest D; Cárceles CM
    J Vet Pharmacol Ther; 2005 Aug; 28(4):343-8. PubMed ID: 16050813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and milk penetration of moxifloxacin after intramuscular administration to lactating goats.
    Cárceles CM; Villamayor L; Escudero E; Marín P; Fernández-Varón E
    Vet J; 2007 Mar; 173(2):452-5. PubMed ID: 16377219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
    Kees MG; Schaeftlein A; Haeberle HA; Kees F; Kloft C; Heininger A
    J Antimicrob Chemother; 2013 Jun; 68(6):1331-7. PubMed ID: 23463212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.
    Stass H; Schühly U; Möller JG; Delesen H
    Clin Pharmacokinet; 2001; 40 Suppl 1():49-55. PubMed ID: 11352442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers.
    Wagenlehner FM; Kees F; Weidner W; Wagenlehner C; Naber KG
    Int J Antimicrob Agents; 2008 Jan; 31(1):21-6. PubMed ID: 18054465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of moxifloxacin in sheep.
    Cárceles CM; Escudero E; Fernández-Varón E; Marín P
    Vet J; 2009 Jun; 180(3):343-7. PubMed ID: 18406644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers.
    Torkildsen G; O'Brien TP
    Clin Ther; 2008 Nov; 30(11):2005-14. PubMed ID: 19108788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration.
    Fuhrmann V; Schenk P; Jaeger W; Ahmed S; Thalhammer F
    J Antimicrob Chemother; 2004 Oct; 54(4):780-4. PubMed ID: 15347636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans.
    Stass H; Kubitza D
    Clin Pharmacokinet; 2001; 40 Suppl 1():57-62. PubMed ID: 11352443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of continuous venovenous haemodialysis on the pharmacokinetics of multiple oral moxifloxacin administration to patients with severe renal dysfunction.
    Stass H; Bührmann S; Mitchell A; Kubitza D; Möller JG; Kribben A; Wenzel RR; Schäfers RF
    Br J Clin Pharmacol; 2007 Dec; 64(6):745-9. PubMed ID: 17555469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study.
    Ullah MA; Shams-Ud-Dowla ; Maruf AA; Azad MA; Shohag MH; Sultana R; Latif AH; Hasnat A
    Clin Ther; 2010 Jul; 32(7):1419-26. PubMed ID: 20678688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switch from intravenous to enteral moxifloxacin in critically ill patients: a pilot study.
    de Smet J; Colpaert K; de Paepe P; van Bocxlaer J; Decruyenaere J; Boussery K
    Scand J Infect Dis; 2012 Nov; 44(11):874-8. PubMed ID: 22804100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of urine alkalization and activated charcoal on the pharmacokinetics of orally administered carprofen in dogs.
    Raekallio MR; Honkavaara JM; Säkkinen MS; Peltoniemi SM
    Am J Vet Res; 2007 Apr; 68(4):423-7. PubMed ID: 17397299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum concentrations and pharmacokinetics of moxifloxacin in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.
    Wiesner G; Martin K; Gertler R; Braun SL; Tassani P; Lange R; Gruber M
    Int J Antimicrob Agents; 2013 May; 41(5):473-6. PubMed ID: 23481660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects.
    Stass H; Nagelschmitz J; Moeller JG; Delesen H
    Int J Clin Pharmacol Ther; 2004 Jan; 42(1):23-9. PubMed ID: 14756383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects.
    Castelli MC; Wong DF; Friedman K; Riley MG
    Clin Ther; 2011 Jul; 33(7):934-45. PubMed ID: 21722960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and tissue residues of moxifloxacin in broiler chickens.
    Goudah A
    Br Poult Sci; 2009 Mar; 50(2):251-8. PubMed ID: 19373726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.